Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN)

Q: What does CUSIP 29337E102 represent in this 13F holders report?

CUSIP 29337E102 is the security identifier for ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q1 2024?

72 institutional investors reported ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q1 2024. Use the holders table for investor-level position and value details.

CUSIP: 29337E102

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 58,923,077
Total 13F shares: 44,456,336
Share change: +5,455,752
Total reported value: $780,753,492
Price per share: $17.59
Number of holders: 72
Value change: +$95,045,035
Number of buys: 40
Number of sells: 25

Quarterly Holders Quick Answers

What is CUSIP 29337E102?
CUSIP 29337E102 identifies ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q2 2024
Previous quarter: Q4 2023

Recent filing periods for CUSIP 29337E102:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
ORBIMED ADVISORS LLC	13F	Company	15%	8,998,338	$124,536,998	—	31 Dec 2023	13F
FMR LLC	13F	Company	8.8%	5,161,242	$71,431,589	—	31 Dec 2023	13F
5AM Venture Management, LLC	13F	Company	8.8%	5,160,975	$71,427,894	—	31 Dec 2023	13F
David P. Bonita	3/4/5	Director, 10%+ Owner	— mixed-class rows	4,207,568 mixed-class rows	$63,552,894	—	02 Jun 2022	3/4/5
5AM Partners VI, LLC	3/4/5	10%+ Owner	— class O/S missing	3,835,975	$57,156,028	—	14 Feb 2024	3/4/5
VR Adviser, LLC	13F	Company	5%	2,954,902	$40,895,844	—	31 Dec 2023	13F
Commodore Capital LP	13F 3/4/5	Company · 10%+ Owner	4.9%	2,901,816	$40,161,133	—	31 Dec 2023	13F 3/4/5
New Enterprise Associates 14, L.P.	3/4/5	10%+ Owner	— class O/S missing	2,611,050	$39,518,242	—	05 Apr 2022	3/4/5
Mark Chin	3/4/5	Director	— mixed-class rows	2,352,572 mixed-class rows	$35,477,530	—	02 Jun 2022	3/4/5
CITADEL ADVISORS LLC	13F	Company	4.1%	2,394,448	$33,139,160	—	31 Dec 2023	13F
RA CAPITAL MANAGEMENT, L.P.	3/4/5 13F	Former 10% owner · Company	3.6% from 13F	2,122,465	$32,123,508	—	23 Feb 2023	3/4/5 13F
Braden M. Leonard	3/4/5	10%+ Owner	— class O/S missing	1,997,774	$30,236,309	—	03 Jan 2023	3/4/5
Fairmount Funds Management LLC	13F	Company	3.6%	2,131,369	$29,498,147	—	31 Dec 2023	13F
BlackRock Finance, Inc.	13F	Company	3.1%	1,849,658	$25,599,268	—	31 Dec 2023	13F
Barbara Dalton	3/4/5	Director	— mixed-class rows	1,566,222 mixed-class rows	$23,576,122	—	02 Jun 2022	3/4/5
VANGUARD GROUP INC	13F	Company	2.1%	1,230,888	$17,035,491	—	31 Dec 2023	13F
Carl Goldfischer	3/4/5	Director	— mixed-class rows	711,880 mixed-class rows	$10,645,656	—	02 Jun 2022	3/4/5
Boxer Capital, LLC	13F	Company	1.1%	646,058	$8,941,443	—	31 Dec 2023	13F
STATE STREET CORP	13F	Company	0.82%	484,515	$6,705,688	—	31 Dec 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.79%	464,657	$6,431,473	—	31 Dec 2023	13F
JANUS HENDERSON GROUP PLC	13F	Company	0.69%	408,514	$5,676,297	—	31 Dec 2023	13F
Woodline Partners LP	13F	Company	0.67%	395,686	$5,476,294	—	31 Dec 2023	13F
Logos Global Management LP	13F	Company	0.52%	307,076	$4,249,932	—	31 Dec 2023	13F
David M. Mott	3/4/5	Director	— mixed-class rows	237,724 mixed-class rows	$3,469,305	—	02 Jun 2022	3/4/5
NORTHERN TRUST CORP	13F	Company	0.38%	224,812	$3,111,399	—	31 Dec 2023	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.27%	158,440	$2,192,810	—	31 Dec 2023	13F
HighVista Strategies LLC	13F	Company	0.23%	137,241	$1,899,415	—	31 Dec 2023	13F
ACUTA CAPITAL PARTNERS, LLC	13F	Company	0.21%	123,876	$1,714,444	—	31 Dec 2023	13F
Nuveen Asset Management, LLC	13F	Company	0.15%	86,629	$1,198,945	—	31 Dec 2023	13F
Bank of New York Mellon Corp	13F	Company	0.14%	80,129	$1,108,985	—	31 Dec 2023	13F
MORGAN STANLEY	13F	Company	0.13%	79,521	$1,100,571	—	31 Dec 2023	13F
BML Capital Management, LLC	13F	Company	0.08%	50,000	$692,000	—	31 Dec 2023	13F
BARCLAYS PLC	13F	Company	0.07%	42,078	$582,359	—	31 Dec 2023	13F
RHUMBLINE ADVISERS	13F	Company	0.06%	37,343	$516,816	—	31 Dec 2023	13F
Kenneth Attie	3/4/5	SVP, CMO	— mixed-class rows	68,200 mixed-class rows	$516,104	—	28 Jan 2022	3/4/5
Swiss National Bank	13F	Company	0.06%	36,473	$504,786	—	31 Dec 2023	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.05%	30,727	$425,262	—	31 Dec 2023	13F
Michael Gray	3/4/5	CFO & COO	— class O/S missing	27,610	$417,877	—	22 Feb 2023	3/4/5
JPMORGAN CHASE & CO	13F	Company	0.04%	23,989	$332,008	—	31 Dec 2023	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.04%	22,698	$314,140	—	31 Dec 2023	13F
CREDIT SUISSE AG/	13F	Company	0.04%	21,895	$303,027	—	31 Dec 2023	13F
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	13F	Company	0.03%	20,330	$281,367	—	31 Dec 2023	13F
Legal & General Group Plc	13F	Company	0.03%	19,665	$272,163	—	31 Dec 2023	13F
STATE OF WISCONSIN INVESTMENT BOARD	13F	Company	0.03%	18,241	$252,455	—	31 Dec 2023	13F
JANE STREET GROUP, LLC	13F	Company	0.03%	15,684	$217,067	—	31 Dec 2023	13F
ALLIANCEBERNSTEIN L.P.	13F	Company	0.03%	14,970	$207,185	—	31 Dec 2023	13F
SG Americas Securities, LLC	13F	Company	0.02%	13,501	$187,000	—	31 Dec 2023	13F
Invesco Ltd.	13F	Company	0.02%	12,488	$172,833	—	31 Dec 2023	13F
MetLife Investment Management, LLC	13F	Company	0.02%	12,345	$170,855	—	31 Dec 2023	13F
Mirae Asset Global Investments Co., Ltd.	13F	Company	0.02%	12,305	$170,301	—	31 Dec 2023	13F

Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) as of Q1 2024

As of 31 Mar 2024, Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) was held by 72 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 44,456,336 shares. The largest 10 holders included ORBIMED ADVISORS LLC, FMR LLC, VR Adviser, LLC, COMMODORE CAPITAL LP, 5AM Venture Management, LLC, Fairmount Funds Management LLC, CITADEL ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., BlackRock Inc., and Logos Global Management LP. This page lists 72 institutional shareholders reporting positions in this security for the Q1 2024 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2024 vs Q4 2023 Across Filers

Q4 2023 holders

Q1 2024 holders

Holder diff

Investor	Q4 2023 Shares	Q1 2024 Shares	Share Diff	Share Chg %	Q4 2023 Value $	Q1 2024 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.